



April 24, 2017

## **Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance**

IRVINE, Calif.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced the appointment of Raymond S. Wysmierski as Director of Compliance, reporting to Carmen McCormick, Esq., Aerie's Chief Compliance Officer and Senior Corporate Counsel. Mr. Wysmierski will be responsible for directing a broad spectrum of compliance activities as Aerie continues preparation for product commercialization. Mr. Wysmierski was most recently Director of Compliance at Avanir Pharmaceuticals, an Otsuka Company. Prior to Avanir, Mr. Wysmierski held compliance-oriented roles at UCB, Inc. and AstraZeneca Pharmaceuticals. Mr. Wysmierski holds a Master's Degree in Jurisprudence and an M.B.A in Health Care Management.

In connection with his acceptance of the position as Director of Compliance, Mr. Wysmierski will receive an award of 16,000 stock options. The stock options will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date. This award was made outside of Aerie's stockholder-approved equity incentive plan and was approved by the Company's Compensation Committee as an inducement material to Mr. Wysmierski's entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4), which requires this public announcement.

### **About Aerie Pharmaceuticals, Inc.**

Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two current product candidates are once-daily intraocular pressure-lowering therapies with novel mechanisms of action to treat patients with glaucoma or ocular hypertension. The NDA for Rhopressa<sup>TM</sup> (netarsudil ophthalmic solution) 0.02% was submitted to the FDA in February 2017. Aerie's second product candidate, Roclatan<sup>TM</sup> (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa<sup>TM</sup> and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a Roclatan<sup>TM</sup> NDA submission is expected to take place in late 2017 or early 2018. Aerie is also focused on the development of additional product candidates and technologies in ophthalmology.

### **Forward-Looking Statements**

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "exploring," "pursuing" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the success, timing and cost of our ongoing and anticipated preclinical studies and clinical trials for our current product candidates, including statements regarding the timing of initiation and completion of the studies and trials; our expectations regarding the clinical effectiveness of our product candidates and results of our clinical trials; the timing of and our ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, our product candidates, including the expected timing of NDA filings for our product candidates; our expectations regarding the commercialization of our product candidates; the potential advantages of our product candidates; our plans to pursue development of our product candidates for additional indications and other therapeutic opportunities; our plans to explore possible uses of our existing proprietary compounds beyond glaucoma; our ability to protect our proprietary technology and enforce our intellectual property rights; and our expectations regarding strategic operations, including our ability to in-license or acquire additional ophthalmic products or product candidates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on regulatory approvals and economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. We discuss many of these

risks in greater detail under the heading "Risk Factors" in the quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170424005064/en/>

Aerie Pharmaceuticals  
Richard Rubino, 908-947-3540  
[rrubino@eriepharma.com](mailto:rrubino@eriepharma.com)

or  
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals  
Investors

Ami Bavishi, 212-213-0006  
[abavishi@burnsmc.com](mailto:abavishi@burnsmc.com)

or  
Media  
Justin Jackson, 212-213-0006  
[jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)

Source: Aerie Pharmaceuticals, Inc.

News Provided by Acquire Media